SYT14

Summary

SYT14 (synaptotagmin 14, HGNC:23143) is a protein-coding gene on chromosome 1q32.2, encoding Synaptotagmin-14 (Q8NB59). May be involved in the trafficking and exocytosis of secretory vesicles in non-neuronal tissues.

This gene is a member of the synaptotagmin gene family and encodes a protein similar to other family members that mediate membrane trafficking in synaptic transmission. The encoded protein is a calcium-independent synaptotagmin. Mutations in this gene are a cause of autosomal recessive spinocerebellar ataxia-11 (SCAR11), and a t(1;3) translocation of this gene has been associated with neurodevelopmental abnormalities. Alternatively spliced transcript variants encoding multiple isoforms have been observed for this gene, and a pseudogene of this gene is located on the long arm of chromosome 4.

Source: NCBI Gene 255928 — RefSeq curated summary.

At a glance

• Gene–disease (curated): autosomal recessive spinocerebellar ataxia 11 (Supportive, GenCC)
• GWAS associations: 15
• Clinical variants (ClinVar): 136 total — 1 pathogenic, 1 likely-pathogenic
• Phenotypes (HPO): 18
• Dosage sensitivity (ClinGen): haploinsufficiency autosomal recessive, triplosensitivity unscored
• MANE Select transcript: NM_001146262

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:23143
Approved symbol	SYT14
Name	synaptotagmin 14
Location	1q32.2
Locus type	gene with protein product
Status	Approved
Aliases	sytXIV, FLJ34198
Ensembl gene	ENSG00000143469
Ensembl biotype	protein_coding
OMIM	610949
Entrez	255928

Gene structure

Transcript identifiers

Ensembl transcripts: 10 — 7 protein_coding, 2 nonsense_mediated_decay, 1 protein_coding_CDS_not_defined

ENST00000367015, ENST00000367019, ENST00000399639, ENST00000472886, ENST00000534859, ENST00000537238, ENST00000637265, ENST00000637945, ENST00000652023, ENST00000699295

RefSeq mRNA: 7 — MANE Select: NM_001146262 NM_001146261, NM_001146262, NM_001146264, NM_001256006, NM_001397544, NM_001397545, NM_153262

CCDS: CCDS31014, CCDS53470, CCDS58058, CCDS91157

Canonical transcript exons

ENST00000367019 — 9 exons

Exon	Start	End
ENSE00001443254	209938217	209938277
ENSE00001443255	210160729	210171315
ENSE00003523023	209952709	209952756
ENSE00003804324	210013633	210013797
ENSE00003805936	210159421	210159477
ENSE00003806100	210100012	210100461
ENSE00003807877	210021039	210021254
ENSE00003808025	210155721	210155910
ENSE00003809888	210094322	210094593

Expression profiles

Bgee: expression breadth broad, 89 present calls, max score 85.78.

FANTOM5 (CAGE): breadth broad, TPM avg 4.0062 / max 186.5970, expressed in 690 samples.

FANTOM5 promoters (6 alternative TSS)

Promoter ID	TPM avg	Samples expressed
8376	2.4359	562
8375	0.8954	380
8373	0.2585	141
8372	0.2375	127
8374	0.1075	36
8371	0.0714	25

Top tissues by expression

222 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	85.78	gold quality
cortical plate	UBERON:0005343	80.81	gold quality
islet of Langerhans	UBERON:0000006	80.21	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	79.73	gold quality
ganglionic eminence	UBERON:0004023	75.88	gold quality
cerebellar hemisphere	UBERON:0002245	73.05	gold quality
cerebellar cortex	UBERON:0002129	72.99	gold quality
stromal cell of endometrium	CL:0002255	72.82	gold quality
right hemisphere of cerebellum	UBERON:0014890	72.58	gold quality
cerebellum	UBERON:0002037	71.25	gold quality
ventricular zone	UBERON:0003053	71.00	gold quality
adenohypophysis	UBERON:0002196	69.02	gold quality
prefrontal cortex	UBERON:0000451	68.30	gold quality
pituitary gland	UBERON:0000007	68.14	gold quality
corpus callosum	UBERON:0002336	66.87	gold quality
adrenal tissue	UBERON:0018303	66.46	gold quality
Brodmann (1909) area 9	UBERON:0013540	65.72	gold quality
anterior cingulate cortex	UBERON:0009835	63.96	gold quality
thyroid gland	UBERON:0002046	63.21	gold quality
hypothalamus	UBERON:0001898	63.12	gold quality
right frontal lobe	UBERON:0002810	63.06	gold quality
left lobe of thyroid gland	UBERON:0001120	62.93	gold quality
neocortex	UBERON:0001950	62.87	gold quality
frontal cortex	UBERON:0001870	62.45	gold quality
nucleus accumbens	UBERON:0001882	62.17	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	62.13	gold quality
testis	UBERON:0000473	61.49	gold quality
right lobe of thyroid gland	UBERON:0001119	61.35	gold quality
brain	UBERON:0000955	61.17	gold quality
amygdala	UBERON:0001876	61.05	gold quality

Single-cell (SCXA)

Detected in 5 experiment(s), a significant marker in 4.

Experiment	Marker?	Max mean expression
E-ENAD-27	yes	10.88
E-GEOD-83139	yes	8.67
E-ANND-3	yes	6.30
E-MTAB-5061	yes	5.85
E-MTAB-6379	no	4.77

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

227 targeting SYT14, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5692B	100.00	71.32	2622
HSA-MIR-5692C	100.00	71.32	2622
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-4776-3P	100.00	68.73	1340
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-126-5P	100.00	72.71	3180
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-6867-5P	100.00	82.21	3464
HSA-MIR-3162-3P	100.00	65.37	363
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-511-3P	99.99	68.85	1467
HSA-MIR-4789-3P	99.99	70.75	2484
HSA-MIR-186-5P	99.99	70.83	3707
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-4482-3P	99.98	72.50	3147
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-548P	99.98	72.25	3784
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-507	99.97	70.11	1915
HSA-MIR-302C-5P	99.97	72.56	3642
HSA-MIR-557	99.96	70.01	1640

Functional genomics

ClinGen dosage: haploinsufficiency 30 (autosomal recessive), triplosensitivity Not yet evaluated (unscored). ClinGen Gene Dosage Map

Literature-anchored findings (GeneRIF, showing 5)

• Constitutional rearrangement of SYT14 may contribute to macrocephaly, cerebral atrophy, seizures and developmental delay. (PMID:17304550)
• A homozygous missense mutation in SYT14, encoding synaptotagmin XIV was identified in a Japanese family in which two siblings have slow progression of a type of autosomal-recessive cerebellar ataxias. (PMID:21835308)
• New DNA sequencing technologies are enabling us to investigate the whole or large targeted proportions of the genome in a rapid, affordable, and comprehensive way. Exome and targeted sequencing SYT14 genes causing ataxia. (PMID:22527681)
• Whole-exome and targeted sequencing have defined the genetic basis of dizziness including new genes causing ataxia: GBA2, TGM6, ANO10 and SYT14 (PMID:24275721)
• SYT14 mRNA expression was detected in the three glioma cell lines, and was highest in the U87MG cell line. The RNAi-mediated knockdown of SYT14 significantly decreased cell proliferation and colony formation in U87MG cells, and caused a moderate increase in apoptosis. Fewer S phase cells and more G2/M phase cells were observed. (PMID:29634997)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	syt14a	ENSDARG00000010934
mus_musculus	Syt14	ENSMUSG00000016200
rattus_norvegicus	Syt14	ENSRNOG00000046139

Paralogs (31): SYT7 (ENSG00000011347), SYT13 (ENSG00000019505), SYT1 (ENSG00000067715), RPH3A (ENSG00000089169), SYTL4 (ENSG00000102362), SYT17 (ENSG00000103528), SYT10 (ENSG00000110975), SYT5 (ENSG00000129990), SYT11 (ENSG00000132718), SYT4 (ENSG00000132872), SYT6 (ENSG00000134207), SYTL2 (ENSG00000137501), SYT16 (ENSG00000139973), SYTL1 (ENSG00000142765), SYT2 (ENSG00000143858), SYTL5 (ENSG00000147041), SYT8 (ENSG00000149043), DOC2A (ENSG00000149927), SYTL3 (ENSG00000164674), TC2N (ENSG00000165929), SYT9 (ENSG00000170743), SYT12 (ENSG00000173227), RPH3AL (ENSG00000181031), C2CD4C (ENSG00000183186), C2CD4A (ENSG00000198535), SYT15 (ENSG00000204176), C2CD4B (ENSG00000205502), SYT3 (ENSG00000213023), C2CD4D (ENSG00000225556), DOC2B (ENSG00000272636), SYT15B (ENSG00000277758)

Protein

Protein identifiers

Synaptotagmin-14 — Q8NB59 (reviewed: Q8NB59)

Alternative names: Synaptotagmin XIV

All UniProt accessions (5): Q8NB59, A0A0A0MTK4, A0A1B0GTF1, A0A1B0GTZ1, A0A8V8TN09

UniProt curated annotations — full annotation on UniProt →

Function. May be involved in the trafficking and exocytosis of secretory vesicles in non-neuronal tissues. Is Ca(2+)-independent.

Subunit / interactions. Homodimer. Can also form heterodimers.

Subcellular location. Membrane.

Tissue specificity. Highly expressed in fetal and adult brain tissue.

Disease relevance. Spinocerebellar ataxia, autosomal recessive, 11 (SCAR11) [MIM:614229] A form of spinocerebellar ataxia, a clinically and genetically heterogeneous group of cerebellar disorders. Patients show progressive incoordination of gait and often poor coordination of hands, speech and eye movements, due to degeneration of the cerebellum with variable involvement of the brainstem and spinal cord. SCAR11 is associated with psychomotor retardation. The disease is caused by variants affecting the gene represented in this entry.

Similarity. Belongs to the synaptotagmin family.

Isoforms (7)

UniProt ID	Names	Canonical?
Q8NB59-1	1	yes
Q8NB59-2	2
Q8NB59-3	3
Q8NB59-4	4
Q8NB59-5	5
Q8NB59-6	6
Q8NB59-7	7

RefSeq proteins (7): NP_001139733, NP_001139734, NP_001139736, NP_001242935, NP_001384473, NP_001384474, NP_694994 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000008	C2_dom	Domain
IPR035892	C2_domain_sf	Homologous_superfamily
IPR043541	SYT14/14L/16	Family

Pfam: PF00168

UniProt features (21 total): splice variant 8, sequence conflict 3, topological domain 2, sequence variant 2, domain 2, region of interest 2, chain 1, transmembrane region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8NB59-F1	65.50	0.29

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 111 (showing top): ACEVEDO_LIVER_CANCER_WITH_H3K27ME3_UP, GSE13762_CTRL_VS_125_VITAMIND_DAY12_DC_DN, GOMF_LIPID_BINDING, GOMF_PHOSPHOLIPID_BINDING, MEISSNER_BRAIN_HCP_WITH_H3K4ME3_AND_H3K27ME3, MEISSNER_NPC_HCP_WITH_H3K4ME2_AND_H3K27ME3, HOELZEL_NF1_TARGETS_UP, VDR_Q6, CHAMP1_TARGET_GENES, E2F5_TARGET_GENES, MIER1_TARGET_GENES, ZNF30_TARGET_GENES, ZNF618_TARGET_GENES, MIR3662, MIR607

GO Biological Process (0):

GO Molecular Function (2): phospholipid binding (GO:0005543), identical protein binding (GO:0042802)

GO Cellular Component (1): membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
lipid binding	1
protein binding	1
cellular anatomical structure	1

Protein interactions and networks

STRING

566 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SYT14	FOSB	P53539	648
SYT14	ANO10	Q9NW15	584
SYT14	SERTAD4	Q9NUC0	519
SYT14	GAL3ST4	Q96RP7	465
SYT14	SYT2	Q8N9I0	462
SYT14	AFG3L2	Q9Y4W6	455
SYT14	LRRN1	Q6UXK5	424
SYT14	CDADC1	Q9BWV3	417
SYT14	COQ8A	Q8NI60	404
SYT14	GCNT4	Q9P109	388
SYT14	ATXN10	Q9UBB4	385
SYT14	RIMS2	Q9UQ26	381
SYT14	SYT12	Q8IV01	380
SYT14	OR13F1	Q8NGS4	376
SYT14	TAFA5	Q7Z5A7	375

IntAct

2 interactions, top by confidence:

A	B	Type	Score
USP7	SYT14	psi-mi:“MI:0407”(direct interaction)	0.440

BioGRID (4): SYT14 (Affinity Capture-Western), SYT14 (Synthetic Lethality), SYT14 (Affinity Capture-RNA), SYT14 (Protein-peptide)

ESM2 similar proteins: A0FGR8, A4IJ05, A7MBL8, F1QGZ6, O08625, O08874, O54785, P15056, P24507, P28028, P34908, P53666, P53670, P53671, Q00944, Q04982, Q07139, Q16513, Q32L23, Q4VX76, Q5FWL4, Q5R8Q5, Q5RCK6, Q5SPC5, Q62136, Q62728, Q62807, Q6XYQ8, Q7TN84, Q80T23, Q812E4, Q86SS6, Q8BWW9, Q8N9U0, Q8NB59, Q8TDW5, Q8VHQ7, Q920M7, Q925C0, Q96C24

Diamond homologs: Q17RD7, Q58G82, Q5HZI2, Q7TN83, Q7TN84, Q8NB59, A4IJ05, O43581, P34693, P41823, P47708, P47709, P59926, P97610, Q06846, Q5R8Q5, Q62747, Q62807, Q8C6N3, Q8IV01, Q8NBV8, Q920M7, Q920N7, Q925B4, Q9BQS2, Q9BSW7, Q9H2B2, Q9R0N6, Q9R0N7, Q9Y2J0, X6R8R1, P24507, Q99N80

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

136 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	1
Uncertain significance	85
Likely benign	22
Benign	20

Top pathogenic / likely-pathogenic (2)

Variant ID	HGVS	Classification
30861	NM_001146262.4(SYT14):c.1316G>A (p.Gly439Asp)	Pathogenic
432092	NM_001146262.4(SYT14):c.13+1G>A	Likely pathogenic

SpliceAI

3158 predictions. Top by Δscore:

Variant	Effect	Δscore
1:209952705:ATAGG:A	acceptor_loss	1.0000
1:209952706:TAGG:T	acceptor_loss	1.0000
1:209952707:A:AT	acceptor_loss	1.0000
1:209952708:G:T	acceptor_loss	1.0000
1:209952757:G:C	donor_loss	1.0000
1:209952758:T:A	donor_loss	1.0000
1:210013631:A:AG	acceptor_gain	1.0000
1:210013632:G:GG	acceptor_gain	1.0000
1:210013632:GT:G	acceptor_gain	1.0000
1:210013793:AATTT:A	donor_gain	1.0000
1:210013794:ATTT:A	donor_gain	1.0000
1:210013795:TTT:T	donor_gain	1.0000
1:210013796:TT:T	donor_gain	1.0000
1:210013796:TTG:T	donor_loss	1.0000
1:210013797:TGTA:T	donor_loss	1.0000
1:210013798:G:GG	donor_gain	1.0000
1:210013798:GTA:G	donor_loss	1.0000
1:210013799:T:TC	donor_loss	1.0000
1:210013800:AAGT:A	donor_loss	1.0000
1:210013801:AG:A	donor_loss	1.0000
1:210015162:A:AG	acceptor_gain	1.0000
1:210021033:A:AG	acceptor_gain	1.0000
1:210021034:A:G	acceptor_gain	1.0000
1:210021036:TA:T	acceptor_loss	1.0000
1:210021037:A:AG	acceptor_gain	1.0000
1:210021037:AGATA:A	acceptor_loss	1.0000
1:210021038:G:GA	acceptor_gain	1.0000
1:210021038:GA:G	acceptor_gain	1.0000
1:210021038:GAT:G	acceptor_gain	1.0000
1:210021038:GATA:G	acceptor_gain	1.0000

AlphaMissense

3770 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:210100127:T:C	L277P	1.000
1:210100202:T:C	L302P	1.000
1:210100268:T:C	F324S	1.000
1:210100325:T:A	V343D	1.000
1:210100331:T:C	F345S	1.000
1:210100337:T:C	L347P	1.000
1:210155824:T:C	L423P	1.000
1:210155829:T:G	Y425D	1.000
1:210155845:G:A	G430E	1.000
1:210155851:T:C	L432P	1.000
1:210155871:G:C	G439R	1.000
1:210160738:T:A	V455D	1.000
1:210160750:T:C	L459P	1.000
1:210160849:C:A	A492D	1.000
1:210160854:T:C	F494L	1.000
1:210160856:T:A	F494L	1.000
1:210160856:T:G	F494L	1.000
1:210160861:T:C	L496P	1.000
1:210160876:T:C	L501P	1.000
1:210160888:T:A	V505E	1.000
1:210160926:G:C	G518R	1.000
1:210160927:G:A	G518D	1.000
1:210160941:G:C	G523R	1.000
1:210160942:G:A	G523D	1.000
1:210160942:G:T	G523V	1.000
1:210160977:T:A	W535R	1.000
1:210160977:T:C	W535R	1.000
1:210160978:G:C	W535S	1.000
1:210160979:G:C	W535C	1.000
1:210160979:G:T	W535C	1.000

dbSNP variants (sampled 300 via entrez): RS1000003766 (1:210042913 G>T), RS1000009397 (1:210027513 G>A), RS1000034855 (1:210000884 A>G), RS1000037799 (1:209999587 C>T), RS1000047591 (1:210128993 A>G,T), RS1000048582 (1:209957080 T>A,G), RS1000052459 (1:210086272 A>C,G), RS1000090300 (1:209993205 C>T), RS1000096424 (1:209999165 C>T), RS1000109524 (1:210120340 G>A), RS1000118230 (1:210036776 A>G), RS1000126188 (1:209945127 C>A), RS1000170439 (1:209942866 T>A), RS1000196581 (1:210079520 C>T), RS1000202184 (1:209936845 A>G,T)

Disease associations

OMIM: gene MIM:610949 | disease phenotypes: MIM:614229

GenCC curated gene-disease

Disease	Classification	Inheritance
autosomal recessive spinocerebellar ataxia 11	Supportive	Autosomal recessive

Mondo (1): autosomal recessive spinocerebellar ataxia 11 (MONDO:0013645)

Orphanet (1): Autosomal recessive cerebellar ataxia-psychomotor delay syndrome (Orphanet:284271)

HPO phenotypes

18 total (18 of 18 shown, HPO-id order):

HPO	Term
HP:0000007	Autosomal recessive inheritance
HP:0000617	Abnormality of ocular smooth pursuit
HP:0000639	Nystagmus
HP:0001249	Intellectual disability
HP:0001251	Ataxia
HP:0001260	Dysarthria
HP:0001263	Global developmental delay
HP:0001272	Cerebellar atrophy
HP:0001288	Gait disturbance
HP:0002015	Dysphagia
HP:0002070	Limb ataxia
HP:0002078	Truncal ataxia
HP:0002317	Unsteady gait
HP:0003677	Slowly progressive
HP:0006855	Cerebellar vermis atrophy
HP:0007772	Impaired smooth pursuit
HP:0007979	Gaze-evoked horizontal nystagmus
HP:0011463	Childhood onset

GWAS associations

15 associations (top):

Study	Trait	p-value
GCST003089_3	Manic episodes in bipolar disorder	7.000000e-06
GCST003996_12	Monobrow	2.000000e-11
GCST004866_6	Alopecia areata	2.000000e-06
GCST006270_1	Drug-induced liver injury in interferon-beta-treated multiple sclerosis	2.000000e-08
GCST006946_19	Worry too long after an embarrassing experience	4.000000e-08
GCST008295_36	Number of decayed, missing and filled tooth surfaces or use of dentures	2.000000e-08
GCST008306_24	Dentures	7.000000e-08
GCST008522_13	Bitter alcoholic beverage consumption	1.000000e-07
GCST008757_8	Alcohol consumption	1.000000e-10
GCST008810_49	Smoking initiation (ever regular vs never regular)	3.000000e-08
GCST009665_11	Breast cancer	8.000000e-07
GCST010002_351	Refractive error	1.000000e-13
GCST010988_269	Adult body size	2.000000e-10
GCST90000050_8	Age at first birth	3.000000e-10
GCST90020053_1	Frailty index	1.000000e-09

EFO canonical traits (8, from GWAS)

EFO ID	Trait name
EFO:0007706	manic or hypomanic episode
EFO:0007906	synophrys measurement
EFO:0009589	worry measurement
EFO:0010078	dentures
EFO:0010092	bitter alcoholic beverage consumption measurement
EFO:0005670	smoking initiation
EFO:0009101	age at first birth measurement
EFO:0009885	frailty measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB variants

1 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs2205986	SYT14	3	3.50	1	interferon beta-1a;interferon beta-1b

CTD chemical–gene interactions

30 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, increases expression, affects expression, decreases methylation	7
bisphenol A	increases expression, decreases methylation	2
sodium arsenite	affects cotreatment, increases abundance, increases expression	2
potassium chromate(VI)	affects cotreatment, decreases expression	2
Aflatoxin B1	decreases methylation, increases methylation	2
perfluorotetradecanoic acid	increases expression	1
titanium dioxide	increases expression	1
trichostatin A	increases expression	1
mono-(2-ethylhexyl)phthalate	decreases expression	1
perfluorooctanoic acid	affects expression	1
manganese chloride	increases abundance, increases expression, affects cotreatment	1
epigallocatechin gallate	affects cotreatment, decreases expression	1
chromium hexavalent ion	decreases expression	1
CGP 52608	affects binding, increases reaction	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
abrine	increases expression	1
dorsomorphin	affects cotreatment, increases expression	1
incobotulinumtoxinA	increases expression	1
MT19c compound	increases expression	1
Decitabine	decreases expression, decreases reaction	1
Vorinostat	increases expression	1
Air Pollutants	increases abundance, increases expression	1
Arsenic	affects cotreatment, increases abundance, increases expression	1
Benzo(a)pyrene	increases methylation	1
Estradiol	affects cotreatment, increases expression	1
Manganese	increases abundance, increases expression, affects cotreatment	1
Silicon Dioxide	increases expression	1
Smoke	decreases expression, decreases reaction	1
Gold Compounds	increases expression	1
Particulate Matter	increases abundance, increases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.